Gail V Matthews
Dados Biográficos
| ID | 7447565 |
|---|---|
| NOME | Gail V Matthews |
| PRENOMES | Gail V |
| SOBRENOME | Matthews |
| ASSINATURA | MATTHEWS G V |
| AFILIAÇÕES | UNSW Sydney |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 9 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 9 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2015 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the Reach-C cohort
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Enhancing the detection and management of acute hepatitis C virus infection
Sem obras proeminentes nesta página.
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Enhancing the detection and management of acute hepatitis C virus infection
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the Reach-C cohort
Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Hepatitis C virus research (8 obras) · Hepatitis C (7 obras) · Internal Medicine (7 obras) · Medicine (7 obras) · Hepatitis C virus (6 obras) · Virus (5 obras) · Hepatitis B Virus Studies (4 obras) · HIV, Drug Use, Sexual Risk (4 obras) · Immunology (4 obras) · Liver Disease Diagnosis and Treatment (3 obras)